A robust prognostic gene expression signature for early stage lung adenocarcinoma

BACKGROUND: Stage I lung adenocarcinoma is usually not treated with adjuvant chemotherapy; however, around half of these patients do not survive 5 years. Therefore, a reliable prognostic biomarker for early stage patients would be critical to identify those most likely to benefit from early addition...

Descripción completa

Detalles Bibliográficos
Autores principales: Krzystanek, Marcin, Moldvay, Judit, Szüts, David, Szallasi, Zoltan, Eklund, Aron Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4761211/
https://www.ncbi.nlm.nih.gov/pubmed/26900477
http://dx.doi.org/10.1186/s40364-016-0058-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4761211/
https://www.ncbi.nlm.nih.gov/pubmed/26900477
http://dx.doi.org/10.1186/s40364-016-0058-3

Ejemplares similares